97614-44-3

Basic information

• Product Name: 2-Deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide 3,5-dibenzoate
• Synonyms: 2-Deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide 3,5-dibenzoate;2-Deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide dibenzoate;2-Deoxy-2-Fluoro-a-D-arabinofuranosyl broMide-3,5-dibenzoate;2-Deoxy-2-fluoro-α-D-arabinofuranosyl BroMide 3,5-Dibenzoate;[(2R,3R,4S,5R)-3-(Benzoyloxy)-5-bromo-4-fluorooxolan-2-yl]methyl benzoate
• CAS NO: 97614-44-3
• Molecular Formula: C₁₉H₁₆BrFO₅
• Molecular Weight: 423.2297432
• Mol File: 97614-44-3.mol
• Article Data: 47

Chemical Properties

• Melting Point: 73℃
• Boiling Point: 492.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.51
• CAS DataBase Reference: 2-Deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide 3,5-dibenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide 3,5-dibenzoate(97614-44-3)
• EPA Substance Registry System: 2-Deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide 3,5-dibenzoate(97614-44-3)

Safety Data

• Hazardous Substances Data: 97614-44-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 97614-44-3 differently. You can refer to the following data:
1. antibiotic related to gentomycin
2. 2-Deoxy-2-fluoro-α-D-arabinofuranosyl Bromide 3,5-Dibenzoate, can be used in the synthesis of Clofarabine (C586890), which is a second generation purine nucleoside analog. It is also an antimetabolite that inhibits DNA synthesis and resists deamination by adenosine deaminase. Antineoplastic.

Upstream product

• 491594-58-2 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranose 
• 14215-97-5 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose 
• 97614-42-1 2-O-(imidazolylsulfonyl)-1,3,5-tri-O-benzoyl-α-D-ribofuranose 
• 22224-41-5 1,3,5-tri-O-benzoyl-α-D-ribofuranoside 
• 97614-43-2 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranose 

Downstream Products

• 134222-06-3 C₂₆H₂₂FN₅O₇ 
• 134222-05-2 C₂₆H₂₂FN₅O₇ 
• 134222-04-1 N²-acetyl-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanine 
• 134222-03-0 C₂₆H₂₂FN₅O₇ 
• 95740-18-4 1-(3',5'-di-O-benzoyl-2'-deoxy-2'-fluoro-β-D-arabinofuranofuranosyl)-5-ethyluracil 
• 128496-05-9 1-(3,5-O-dibenzoyl-2-fluoro-β-D-arabinofuranosyl)-5-fluorocytosine 
• 132723-16-1 (2R,3R,4S,5R)-4-Fluoro-2-hydroxymethyl-5-purin-7-yl-tetrahydro-furan-3-ol 
• 109304-16-7 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)purine 
• 132723-15-0 C₂₄H₁₉FN₄O₅ 
• 132723-01-4 9-(3',5'-di-O-benzoyl-2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-9H-purine 
• 132723-14-9 C₂₄H₁₉FN₄O₅ 
• 97614-45-4 5-iodo-1-(2'-deoxy-2'-fluoro-3',5'-di-O-benzoyl-β-D-arabinofuranosyl)uracil 
• 97614-46-5 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl)-5-iodouracil 
• 128495-99-8 1-(3,5-O-dibenzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)cytosine 

Relevant articles and documents

S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS

Various embodiments provide STOPS? polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS? modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS? modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

Synthesis of Rovafovir Etalafenamide (Part IV): Evolution of the Synthetic Process to the Fluorinated Nucleoside Fragment

Fluorinated nucleoside 1 is a key starting material in the synthesis of rovafovir etalafenamide (2), a novel nucleotide reverse transcriptase inhibitor under development at Gilead Sciences for the treatment of HIV. While an initial manufacturing route enabled the production of 1 to support clinical development, alternative approaches were explored to further enhance manufacturing effectiveness, improve processing time, reduce cost, and minimize the environmental impact. Toward this end, two new routes were developed to a key synthetic intermediate, which was converted to 1 using a new protecting group strategy. The new chemistry led to improvements in the manufacturing process while reducing the overall process mass intensity (PMI).

ANTIVIRAL DRUG

PROBLEM TO BE SOLVED: To provide a nucleic acid analog having excellent antiviral activity (particularly anti-hepatitis B virus activity). SOLUTION: The invention provides a compound represented by the formula (I) in the figure, where each symbol is as defined in the specification, or a salt thereof. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT